Sign in or create an account to add this stock to your watchlist.
About Achaogen (NASDAQ:AKAO)
Achaogen, Inc., a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKAO
CUSIPN/A
Phone650-800-3636
Debt
Debt-to-Equity Ratio0.24
Current Ratio7.01
Quick Ratio7.01
Price-To-Earnings
Trailing P/E Ratio-3.93
Forward P/E Ratio-3.63
P/E GrowthN/A
Sales & Book Value
Annual Sales$11.18 million
Price / Sales49.89
Cash FlowN/A
Price / CashN/A
Book Value$2.30 per share
Price / Book5.41
Profitability
EPS (Most Recent Fiscal Year)($3.17)
Net Income$-125,610,000.00
Net Margins-2,384.08%
Return on Equity-97.86%
Return on Assets-62.39%
Miscellaneous
Employees230
Outstanding Shares44,800,000
Achaogen (NASDAQ:AKAO) Frequently Asked Questions
What is Achaogen's stock symbol?
Achaogen trades on the NASDAQ under the ticker symbol "AKAO."
How were Achaogen's earnings last quarter?
Achaogen (NASDAQ:AKAO) released its earnings results on Friday, May, 4th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.89) by $0.17. The biopharmaceutical company earned $2.14 million during the quarter, compared to analysts' expectations of $1.25 million. Achaogen had a negative net margin of 2,384.08% and a negative return on equity of 97.86%. View Achaogen's Earnings History.
What price target have analysts set for AKAO?
9 Wall Street analysts have issued 12 month target prices for Achaogen's shares. Their predictions range from $16.00 to $29.00. On average, they expect Achaogen's stock price to reach $22.1250 in the next year. View Analyst Ratings for Achaogen.
What are Wall Street analysts saying about Achaogen stock?
Here are some recent quotes from research analysts about Achaogen stock:
- 1. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (5/9/2018)
- 2. Mizuho analysts commented, "We are reducing our PT from $28 to $20 based on a worst-case scenario analysis assuming no revenues from BSI or any other potential usages and an additional capital raise of $200 million in 2019 (an amount we see as adequate to carry the company to break-even point). We would be buyers on weakness as we believe Achaogen has an approvable drug in cUTI and there could be upside potential from Plazomicin in Carbapenem- resistant enterobacteriaceae (CRE) cases over time." (5/3/2018)
- 3. Needham & Company LLC analysts commented, "Plazomicin will be discussed at an FDA Advisory Committee (AdCom) mtg 5/2/18. Achaogen completed two Phase 3 trials, a standard cUTI trial (EPIC) and the other a descriptive trial in patients with HABP/VABP or bloodstream infections caused by Carbapenem Resistant Enterobacteriaceae (CRE; CARE). Both trials had positive outcomes, w/ the latter surprisingly demonstrating superiority to comparator colistin. Achaogen is seeking a label in both cUTI and Bloodstream infections, although Bloodstream is controversial given the descriptive nature of the CARE trial. The Avycaz and Cresemba AdCom mtgs are most relevant to analysis of the plazomicin mtg and we have a modest bias towards a vote in favor of including both indications on plazomicin label. Our note details recent antibiotic FDA reviews and individual voting histories. BUY." (4/30/2018)
- 4. HC Wainwright analysts commented, "We find no big surprises in the FDA analyses. This morning, FDA released its Briefing Document for the May 2, 2018 meeting of the Antimicrobial Drugs Advisory Committee (AMDAC) to review the NDA for Achaogen’s plazomicin for the proposed indications for the treatment of complicated urinary tract infection (cUTI), including acute pyelonephritis (AP); and bloodstream infections (BSI), in adults." (4/30/2018)
Are investors shorting Achaogen?
Achaogen saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 14,173,240 shares, an increase of 13.5% from the April 13th total of 12,483,137 shares. Based on an average daily trading volume, of 1,389,113 shares, the days-to-cover ratio is presently 10.2 days. Currently, 55.9% of the company's shares are short sold.
Who are some of Achaogen's key competitors?
Some companies that are related to Achaogen include Evotec A.G. (EVTCY), Insmed (INSM), Intercept Pharmaceuticals (ICPT), Corcept Therapeutics (CORT), Spectrum Pharmaceuticals (SPPI), AnaptysBio (ANAB), Puma Biotechnology (PBYI), Enanta Pharmaceuticals (ENTA), Akcea Therapeutics (AKCA), Xencor (XNCR), Madrigal Pharmaceuticals (MDGL), MyoKardia (MYOK), Motif (MTFB), Phibro Animal Health (PAHC) and Prestige Brands (PBH).
Who are Achaogen's key executives?
Achaogen's management team includes the folowing people:
- Mr. Blake Wise, CEO & Director (Age 47)
- Dr. Kenneth J. Hillan, Pres of R&D, Pres of Achaogen and Director (Age 57)
- Dr. Floyd E. Romesberg Ph.D., Principal Scientific Founder and Advisor
- Dr. Nathaniel E. David A.B., Ph.D., Principal Entrepreneurial Founder (Age 50)
- Mr. Tobin C. Schilke, Chief Financial Officer & Principal Accounting Officer (Age 43)
Has Achaogen been receiving favorable news coverage?
Headlines about AKAO stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Achaogen earned a coverage optimism score of 0.23 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 46.64 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Achaogen's major shareholders?
Achaogen's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.47%), Prosight Management LP (1.48%), UBS Group AG (0.66%), Candriam Luxembourg S.C.A. (0.50%), Gabelli Funds LLC (0.39%) and Fiera Capital Corp (0.37%). Company insiders that own Achaogen stock include Blake Wise, Equity Opportunities Iv Growth, Gary Loeb, Ian Friedland, Kenneth J Hillan, Lee Swem, Robert W Duggan, Tobin Schilke and Zeryn Sarpangal. View Institutional Ownership Trends for Achaogen.
Which major investors are selling Achaogen stock?
AKAO stock was sold by a variety of institutional investors in the last quarter, including Fiera Capital Corp. Company insiders that have sold Achaogen company stock in the last year include Blake Wise, Gary Loeb, Kenneth J Hillan, Lee Swem and Tobin Schilke. View Insider Buying and Selling for Achaogen.
Which major investors are buying Achaogen stock?
AKAO stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, RMB Capital Management LLC, Gabelli Funds LLC, Prosight Management LP, Gamco Investors INC. ET AL, BlackRock Inc., Engineers Gate Manager LP and Candriam Luxembourg S.C.A.. Company insiders that have bought Achaogen stock in the last two years include Equity Opportunities Iv Growth and Robert W Duggan. View Insider Buying and Selling for Achaogen.
How do I buy shares of Achaogen?
Shares of AKAO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Achaogen's stock price today?
One share of AKAO stock can currently be purchased for approximately $12.45.
How big of a company is Achaogen?
Achaogen has a market capitalization of $557.71 million and generates $11.18 million in revenue each year. The biopharmaceutical company earns $-125,610,000.00 in net income (profit) each year or ($3.17) on an earnings per share basis. Achaogen employs 230 workers across the globe.
How can I contact Achaogen?
Achaogen's mailing address is 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-800-3636 or via email at [email protected]
MarketBeat Community Rating for Achaogen (AKAO)
MarketBeat's community ratings are surveys of what our community members think about Achaogen and other stocks. Vote "Outperform" if you believe AKAO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKAO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Achaogen (NASDAQ:AKAO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for Achaogen in the last 12 months. Their average twelve-month price target is $22.1250, suggesting that the stock has a possible upside of 77.71%. The high price target for AKAO is $29.00 and the low price target for AKAO is $16.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.89 | 3.00 | 2.90 | 2.89 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $22.1250 | $23.1250 | $25.4444 | $25.6250 |
| Price Target Upside: | 77.71% upside | 110.23% upside | 131.73% upside | 82.77% upside |
Achaogen (NASDAQ:AKAO) Consensus Price Target History
Achaogen (NASDAQ:AKAO) Analyst Ratings History
Show:
(Data available from 5/20/2016 forward)
Achaogen (NASDAQ:AKAO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Achaogen (NASDAQ AKAO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.80%
Institutional Ownership Percentage: 76.88%
Achaogen (NASDAQ AKAO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/25/2018 | Lee Swem | Insider | Sell | 900 | $15.99 | $14,391.00 | 35,919 |  |
| 5/3/2018 | Robert W Duggan | Major Shareholder | Buy | 976,880 | $11.33 | $11,068,050.40 | 8,027,627 | |
| 4/27/2018 | Robert W Duggan | Major Shareholder | Buy | 102,849 | $12.96 | $1,332,923.04 | 7,028,153 | |
| 4/25/2018 | Robert W Duggan | Major Shareholder | Buy | 77,247 | $13.02 | $1,005,755.94 | 7,028,153 | |
| 4/23/2018 | Robert W Duggan | Major Shareholder | Buy | 468,337 | $13.06 | $6,116,481.22 | 6,602,269 | |
| 4/19/2018 | Robert W Duggan | Major Shareholder | Buy | 119,700 | $12.76 | $1,527,372.00 | 6,602,269 | |
| 4/4/2018 | Robert W Duggan | Major Shareholder | Buy | 47,361 | $12.44 | $589,170.84 | 6,411,108 | |
| 4/2/2018 | Robert W Duggan | Major Shareholder | Buy | 20,000 | $12.51 | $250,200.00 | 6,411,108 | |
| 3/28/2018 | Robert W Duggan | Major Shareholder | Buy | 30,000 | $12.44 | $373,200.00 | 6,391,108 | |
| 3/20/2018 | Robert W Duggan | Major Shareholder | Buy | 36,300 | $11.12 | $403,656.00 | 6,336,108 | |
| 3/15/2018 | Robert W Duggan | Major Shareholder | Buy | 49,660 | $11.36 | $564,137.60 | 6,294,808 | |
| 3/13/2018 | Kenneth J. Hillan | Insider | Sell | 2,735 | $11.74 | $32,108.90 | | |
| 3/12/2018 | Robert W Duggan | Major Shareholder | Buy | 20,000 | $11.39 | $227,800.00 | 6,255,148 | |
| 3/9/2018 | Robert W Duggan | Major Shareholder | Buy | 50,000 | $11.41 | $570,500.00 | 6,255,148 | |
| 3/2/2018 | Robert W Duggan | Major Shareholder | Buy | 527,396 | $10.31 | $5,437,452.76 | 5,697,752 | |
| 2/28/2018 | Robert W Duggan | Major Shareholder | Buy | 20,000 | $10.70 | $214,000.00 | 5,697,752 | |
| 2/21/2018 | Blake Wise | CEO | Sell | 1,640 | $10.67 | $17,498.80 | | |
| 2/21/2018 | Kenneth J. Hillan | Insider | Sell | 4,606 | $10.67 | $49,146.02 | | |
| 2/21/2018 | Tobin Schilke | CFO | Sell | 1,108 | $10.67 | $11,822.36 | | |
| 2/14/2018 | Robert W Duggan | Major Shareholder | Buy | 10,000 | $10.96 | $109,600.00 | 5,668,310 | |
| 1/5/2018 | Robert W Duggan | Major Shareholder | Buy | 50,000 | $11.51 | $575,500.00 | 5,617,752 | |
| 1/3/2018 | Robert W Duggan | Major Shareholder | Buy | 15,000 | $10.89 | $163,350.00 | 5,617,752 | |
| 12/18/2017 | Robert W Duggan | Major Shareholder | Buy | 95,012 | $11.13 | $1,057,483.56 | 5,602,752 | |
| 9/26/2017 | Blake Wise | COO | Sell | 3,576 | $15.99 | $57,180.24 | | |
| 9/26/2017 | Gary Loeb | General Counsel | Sell | 1,146 | $15.99 | $18,324.54 | | |
| 6/12/2017 | Tobin Schilke | CFO | Sell | 2,066 | $21.53 | $44,480.98 | | |
| 1/26/2017 | Gary Loeb | General Counsel | Sell | 521 | $16.78 | $8,742.38 | | |
| 1/26/2017 | Ian Friedland | Insider | Sell | 695 | $16.78 | $11,662.10 | | |
| 1/26/2017 | Kenneth J. Hillan | CEO | Sell | 1,431 | $16.78 | $24,012.18 | | |
| 1/26/2017 | Tobin Schilke | CFO | Sell | 955 | $16.78 | $16,024.90 | | |
| 1/26/2017 | Zeryn Sarpangal | VP | Sell | 781 | $16.78 | $13,105.18 | | |
| 12/19/2016 | Equity Opportunities Iv Growth | Major Shareholder | Buy | 500,000 | $13.50 | $6,750,000.00 | | |
| 9/27/2016 | Blake Wise | COO | Sell | 3,632 | $4.30 | $15,617.60 | | |
| 9/27/2016 | Zeryn Sarpangal | VP | Sell | 1,069 | $4.30 | $4,596.70 | | |
| 3/17/2016 | Ian Friedland | Insider | Sell | 1,772 | $3.22 | $5,705.84 | 32,728 | |
| 3/17/2016 | Kenneth J Hillan | CEO | Sell | 3,572 | $3.22 | $11,501.84 | 61,628 | |
(Data available from 1/1/2013 forward)
Achaogen (NASDAQ AKAO) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Achaogen (AKAO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 17 at 11:05 AM |
| Achaogen (AKAO) Insider Lee Swem Sells 900 Shares
www.americanbankingnews.com - May 15 at 8:34 PM |
 | Achaogen: Explicating The Prospects Of C-Scape
seekingalpha.com - May 13 at 8:09 AM |
| Wedbush Analysts Increase Earnings Estimates for Achaogen (AKAO)
www.americanbankingnews.com - May 11 at 9:50 AM |
| Achaogen: A Long-Term Holding With Tremendous Prospects
seekingalpha.com - May 11 at 8:07 AM |
| Short Interest in Achaogen (AKAO) Expands By 13.5%
www.americanbankingnews.com - May 11 at 3:29 AM |
| Research Analysts Offer Predictions for Achaogen's FY2018 Earnings (AKAO)
www.americanbankingnews.com - May 10 at 8:41 AM |
| Achaogen (AKAO) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - May 9 at 5:09 PM |
| Achaogen (AKAO) Forecasted to Post Q2 2018 Earnings of ($1.03) Per Share
www.americanbankingnews.com - May 9 at 8:39 AM |
| Leerink Swann Weighs in on Achaogen's Q2 2018 Earnings (AKAO)
www.americanbankingnews.com - May 9 at 8:39 AM |
| Achaogen: In The Middle Of A Temporary Difficulty There Is A Stellar Opportunity
seekingalpha.com - May 9 at 8:07 AM |
| Editor's Notes: Visiting The Achaogen And Axon Battlegrounds
seekingalpha.com - May 8 at 5:52 PM |
| Robert W. Duggan Buys 976,880 Shares of Achaogen (AKAO) Stock
www.americanbankingnews.com - May 7 at 7:20 PM |
| Achaogen After Ad Comm
seekingalpha.com - May 7 at 5:47 PM |
| Achaogen (AKAO) Stock Rating Lowered by Guggenheim
www.americanbankingnews.com - May 7 at 2:58 PM |
| SunTrust Banks Comments on Achaogen's FY2019 Earnings (AKAO)
www.americanbankingnews.com - May 7 at 5:04 AM |
| Achaogen (AKAO) Expected to Post Q1 2019 Earnings of ($0.88) Per Share
www.americanbankingnews.com - May 7 at 4:38 AM |
 | Edited Transcript of AKAO earnings conference call or presentation 4-May-18 12:30pm GMT
finance.yahoo.com - May 5 at 5:55 PM |
| Achaogen (AKAO) Issues Earnings Results
www.americanbankingnews.com - May 5 at 1:33 PM |
| Analysts Anticipate Achaogen (AKAO) Will Announce Quarterly Sales of $1.25 Million
www.americanbankingnews.com - May 5 at 4:21 AM |
| Achaogen (AKAO) Given New $16.00 Price Target at SunTrust Banks
www.americanbankingnews.com - May 4 at 10:31 PM |
| My Favorite Investment For The Coming Biotech Bull Market (Bret Jensen)
seekingalpha.com - May 4 at 8:08 AM |
| Your Daily Pharma Scoop: Achaogen Mixed Ad Com, Esperion Mixed Results, InVivo Up On Old Data
seekingalpha.com - May 4 at 8:08 AM |
 | BRIEF-Achaogen Q1 loss per share $1.06
www.reuters.com - May 4 at 8:08 AM |
| Rounds Report: Eleven Train Heads Further North While Achaogen Gained Mixed ADCOM Results
seekingalpha.com - May 4 at 8:08 AM |
| Unjustified Sell-Off In Achaogen After FDA Panel Vote Provides A Golden Opportunity
seekingalpha.com - May 4 at 8:08 AM |
| Achaogen: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 8:08 AM |
| Mizuho Reiterates "Buy" Rating for Achaogen (AKAO)
www.americanbankingnews.com - May 3 at 12:06 PM |
 | Why Achaogen Shares Are Getting Crushed On Plazomicin FDA News
feeds.benzinga.com - May 3 at 11:37 AM |
| Achaogen (AKAO) Expected to Post Earnings of -$0.91 Per Share
www.americanbankingnews.com - May 3 at 10:17 AM |
| BRIEF-Achaogen Says FDA Advisory Committee Voted In Favor Of Plazomicin For Urinary Tract Infections
www.reuters.com - May 3 at 8:06 AM |
 | AKAO Slumps On FDA Panel Vote, ESPR Awaits Data In May, STAA Shines
www.nasdaq.com - May 3 at 8:06 AM |
| Peninsula drug developer's stock plunges, but its antibiotic still could win FDA approval
finance.yahoo.com - May 3 at 8:06 AM |
| Why the Prestigious Mayo Clinic is a 10% Holder of This Undiscovered Public Company
finance.yahoo.com - May 3 at 8:06 AM |
| Achaogen (AKAO) Scheduled to Post Earnings on Friday
www.americanbankingnews.com - May 2 at 8:15 PM |
 | Achaogen Announces FDA Advisory Committee Voted Unanimously in Favor of Plazomicin for Treatment of Adults with ...
globenewswire.com - May 2 at 5:45 PM |
| Achaogen Announces FDA Advisory Committee Voted Unanimously in Favor of Plazomicin for Treatment of Adults with Complicated Urinary Tract Infections
finance.yahoo.com - May 2 at 5:45 PM |
| Achaogen (AKAO) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - May 2 at 1:07 PM |
| Market Trends Toward New Normal in Cohen & Steers, Achaogen, Ares Commercial Real Estate, CONMED, Marcus ...
globenewswire.com - May 2 at 8:11 AM |
| Market Trends Toward New Normal in Cohen & Steers, Achaogen, Ares Commercial Real Estate, CONMED, Marcus, and First Defiance Financial — Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - May 2 at 8:11 AM |
| Achaogen Stock Trading Halted Today
finance.yahoo.com - May 2 at 8:11 AM |
| Achaogen shares halted pending outcome of Ad Com review
seekingalpha.com - May 2 at 8:04 AM |
| Achaogen (AKAO) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 1 at 6:06 PM |
| Investors Purchase High Volume of Put Options on Achaogen (AKAO)
www.americanbankingnews.com - May 1 at 7:16 AM |
 | Options Traders Expect Huge Moves in Achaogen (AKAO) Stock
www.zacks.com - April 30 at 5:21 PM |
| Premarket Gainers as of 9:05 am (04/30/2018)
seekingalpha.com - April 30 at 5:21 PM |
 | Achaogen (AKAO) on Watch After FDA Posts Briefing Documents for Plazomicin
www.streetinsider.com - April 30 at 5:21 PM |
| Achaogen (AKAO) Receives Buy Rating from Needham & Company LLC
www.americanbankingnews.com - April 30 at 1:22 PM |
| Achaogen's (AKAO) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - April 30 at 1:22 PM |
| FDA Ad Com review for Achaogen's plazomicin May 2
seekingalpha.com - April 30 at 8:49 AM |
Achaogen (NASDAQ:AKAO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Achaogen (NASDAQ:AKAO) Income Statement, Balance Sheet and Cash Flow Statement
Achaogen (NASDAQ AKAO) Stock Chart for Sunday, May, 20, 2018
Loading chart…
